Abstract
RNA interference (RNAi) is an evolutionary conserved post-transcriptional gene silencing mechanism, in which double stranded RNA effector molecules trigger the degradation of complementary mRNA transcripts. The use of RNAi to reduce gene expression with high specificity and ready availability is a powerful tool for reverse genetics and provides great therapeutic potential for targeting diseases caused by the expression of a deleterious gene or mutant allele, e.g. cancer and viral infections. Besides the known preferences of the RNAi technique, there is a need for the development of improved small double stranded silencing triggers with long lasting silencing activity and maximum specificity. The introduction of chemically modified nucleotides into short interfering RNAs (siRNAs) is currently the method of choice. In this review, we summarize the effects of various modifications on siRNA sub-cellular localization and silencing activity, discuss ideal chemical modifications and positions within siRNAs suited for their use in medical therapies and present a new perspective to study siRNA mediated silencing in vivo by fluorescence correlation spectroscopy (FCS) and fluorescence cross-correlation spectroscopy (FCCS) to further improve RNAi-based pharmaceuticals.
Keywords: siRNA, RISC, Argonaute 2, Exportin-5, fluorescence, microinjection, live cell imaging, in vivo FCS/ FCCS
Current Pharmaceutical Design
Title: siRNA Modifications and Sub-Cellular Localization: A Question of Intracellular Transport?
Volume: 14 Issue: 34
Author(s): T. Ohrt and P. Schwille
Affiliation:
Keywords: siRNA, RISC, Argonaute 2, Exportin-5, fluorescence, microinjection, live cell imaging, in vivo FCS/ FCCS
Abstract: RNA interference (RNAi) is an evolutionary conserved post-transcriptional gene silencing mechanism, in which double stranded RNA effector molecules trigger the degradation of complementary mRNA transcripts. The use of RNAi to reduce gene expression with high specificity and ready availability is a powerful tool for reverse genetics and provides great therapeutic potential for targeting diseases caused by the expression of a deleterious gene or mutant allele, e.g. cancer and viral infections. Besides the known preferences of the RNAi technique, there is a need for the development of improved small double stranded silencing triggers with long lasting silencing activity and maximum specificity. The introduction of chemically modified nucleotides into short interfering RNAs (siRNAs) is currently the method of choice. In this review, we summarize the effects of various modifications on siRNA sub-cellular localization and silencing activity, discuss ideal chemical modifications and positions within siRNAs suited for their use in medical therapies and present a new perspective to study siRNA mediated silencing in vivo by fluorescence correlation spectroscopy (FCS) and fluorescence cross-correlation spectroscopy (FCCS) to further improve RNAi-based pharmaceuticals.
Export Options
About this article
Cite this article as:
Ohrt T. and Schwille P., siRNA Modifications and Sub-Cellular Localization: A Question of Intracellular Transport?, Current Pharmaceutical Design 2008; 14 (34) . https://dx.doi.org/10.2174/138161208786898798
DOI https://dx.doi.org/10.2174/138161208786898798 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?
Current Drug Metabolism Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Using Fragment-Based Technologies to Target Protein-Protein Interactions
Current Pharmaceutical Design Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy